FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367303789> ?p ?o ?g. }

• W4367303789 abstract "<h3>Objective:</h3> To describe a case of post-COVID-19 GFAP astrocytopathy presenting with meningoencephalomyelitis. <h3>Background:</h3> Glial fibrillary acidic protein (GFAP) astrocytopathy is a newly described autoimmune disorder that presents with meningoencephalitis, myelitis and cerebellar dysfunction. Differential diagnosis includes inflammatory, neoplastic and infectious etiologies. GFAP astrocytopathy associated meningoencephalomyelitis is a rare, but treatable neurologic sequela of COVID-19. <h3>Design/Methods:</h3> N/A <h3>Results:</h3> A 62-year-old man presented with progressive confusion, recurrent falls, and weight loss with initial symptom onset during COVID-19 infection 6 weeks prior. MRI showed patchy parenchymal and ependymal enhancement in the brainstem and temporal lobe as well as T2 hyperintensity throughout the cervical and thoracic cord consistent with transverse myelitis. Four lumbar punctures demonstrated elevated protein between 100–200 mg/dl and significant lymphocytic pleocytosis with 300–600 nucleated cells. Extensive infectious work-up was negative. Malignancy work-up showed PET-CT avidity in the spinal cord and positive MYD88 mutation in the CSF, possibly indicating a lymphoproliferative condition. However, CSF cytology, CSF flow cytometry and a bone marrow biopsy showed no evidence of malignancy on repeated testing. CSF autoimmune encephalopathy panel demonstrated high titers of GFAP antibodies. Initial treatment included pulse-dose steroids and IVIG with minimal improvement in cognition. He was then treated with pulse-dose steroids and rituximab with markedly improved cognition, motor function and appetite. Subsequent 2-month MRI demonstrated partial resolution of his cerebral and spinal lesions. <h3>Conclusions:</h3> Subacute meningoencephalitis, with or without myelitis, is a typical presentation of GFAP astrocytopathy. Other symptoms include ataxia, blurred vision with optic disc edema, dysautonomia, seizures, area postrema syndrome and psychiatric symptoms. Most patients have a steroid responsive monophasic course, but approximately 20% of patients have relapsing disease. GFAP astrocytopathy should be on the differential for meningoencephalomyelitis, especially with infectious prodrome, such as COVID-19 infection. Early recognition and treatment can lead to improvement of neurologic deficits and a good outcome. <b>Disclosure:</b> Dr. Song has nothing to disclose. Dr. Oetjen has nothing to disclose. Dr. Harrold has nothing to disclose. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Dietrich has received publishing royalties from a publication relating to health care. Kien-Ninh Ly has nothing to disclose. Dr. Venna has nothing to disclose." @default.
• W4367303789 created "2023-04-29" @default.
• W4367303789 creator A5012323591 @default.
• W4367303789 creator A5049734695 @default.
• W4367303789 creator A5049880329 @default.
• W4367303789 creator A5053451383 @default.
• W4367303789 creator A5081551152 @default.
• W4367303789 creator A5091540766 @default.
• W4367303789 date "2023-04-25" @default.
• W4367303789 modified "2023-09-30" @default.
• W4367303789 title "GFAP astrocytopathy presenting after COVID-19 infection with meningoencephalomyelitis and good recovery with immunotherapy (P14-4.001)" @default.
• W4367303789 doi "https://doi.org/10.1212/wnl.0000000000202122" @default.
• W4367303789 hasPublicationYear "2023" @default.
• W4367303789 type Work @default.
• W4367303789 citedByCount "0" @default.
• W4367303789 crossrefType "proceedings-article" @default.
• W4367303789 hasAuthorship W4367303789A5012323591 @default.
• W4367303789 hasAuthorship W4367303789A5049734695 @default.
• W4367303789 hasAuthorship W4367303789A5049880329 @default.
• W4367303789 hasAuthorship W4367303789A5053451383 @default.
• W4367303789 hasAuthorship W4367303789A5081551152 @default.
• W4367303789 hasAuthorship W4367303789A5091540766 @default.
• W4367303789 hasConcept C118552586 @default.
• W4367303789 hasConcept C142724271 @default.
• W4367303789 hasConcept C204232928 @default.
• W4367303789 hasConcept C2777483564 @default.
• W4367303789 hasConcept C2777704947 @default.
• W4367303789 hasConcept C2778621254 @default.
• W4367303789 hasConcept C2779651940 @default.
• W4367303789 hasConcept C2780495277 @default.
• W4367303789 hasConcept C2780775167 @default.
• W4367303789 hasConcept C71924100 @default.
• W4367303789 hasConceptScore W4367303789C118552586 @default.
• W4367303789 hasConceptScore W4367303789C142724271 @default.
• W4367303789 hasConceptScore W4367303789C204232928 @default.
• W4367303789 hasConceptScore W4367303789C2777483564 @default.
• W4367303789 hasConceptScore W4367303789C2777704947 @default.
• W4367303789 hasConceptScore W4367303789C2778621254 @default.
• W4367303789 hasConceptScore W4367303789C2779651940 @default.
• W4367303789 hasConceptScore W4367303789C2780495277 @default.
• W4367303789 hasConceptScore W4367303789C2780775167 @default.
• W4367303789 hasConceptScore W4367303789C71924100 @default.
• W4367303789 hasLocation W43673037891 @default.
• W4367303789 hasOpenAccess W4367303789 @default.
• W4367303789 hasPrimaryLocation W43673037891 @default.
• W4367303789 hasRelatedWork W2055306896 @default.
• W4367303789 hasRelatedWork W2093788700 @default.
• W4367303789 hasRelatedWork W2126457765 @default.
• W4367303789 hasRelatedWork W2160133007 @default.
• W4367303789 hasRelatedWork W2182719059 @default.
• W4367303789 hasRelatedWork W2419523509 @default.
• W4367303789 hasRelatedWork W2793664442 @default.
• W4367303789 hasRelatedWork W3096431816 @default.
• W4367303789 hasRelatedWork W3111325197 @default.
• W4367303789 hasRelatedWork W4303198220 @default.
• W4367303789 isParatext "false" @default.
• W4367303789 isRetracted "false" @default.
• W4367303789 workType "article" @default.